当前位置:首页 - 行情中心 - 华兰疫苗(301207) - 财务分析 - 利润表

华兰疫苗

(301207)

  

流通市值:103.79亿  总市值:103.86亿
流通股本:6.01亿   总股本:6.01亿

利润表

报告期2025-06-302025-03-312024-12-312024-09-30
公司类型通用通用通用通用
一、营业总收入59,961,774.2724,282,534.721,127,812,323.85957,363,018.62
  营业收入59,961,774.2724,282,534.721,127,812,323.85957,363,018.62
二、营业总成本163,447,081.2349,573,022.32961,283,918.27757,727,172.19
  营业成本14,837,205.73,400,793.07212,558,788.13181,380,089.52
  税金及附加2,848,922.881,458,933.0610,606,122.828,383,073.02
  销售费用28,993,900.3714,617,192.32501,385,044.85411,829,871.25
  管理费用34,538,407.887,947,905.5281,157,726.3783,284,696.66
  研发费用82,323,158.6822,115,565.91162,640,277.7480,510,272.88
  财务费用-94,514.2832,632.44-7,064,041.64-7,660,831.14
  其中:利息费用2,550,000.021,316,666.686,100,000.024,400,000.02
  其中:利息收入2,729,855.271,313,039.4413,215,392.612,124,492.32
三、其他经营收益
  加:公允价值变动收益10,279,395.195,452,133.5224,300,582.7719,027,316.14
  加:投资收益39,067,003.7620,064,785.0176,072,994.6455,812,973.56
  资产处置收益---140,144.03-140,144.03
  资产减值损失(新)12,277,453.71,046,468.97-74,225,065.72-
  信用减值损失(新)49,290,397.9132,636,845.679,429,587.4722,493,940.1
  其他收益4,701,403.792,558,547.6412,889,666.469,041,487.2
四、营业利润12,130,347.3936,468,293.21214,856,027.17305,871,419.4
  加:营业外收入208,000-1,603,558.251,547,266.25
  减:营业外支出1,136,403.451,130,559.991,913,859.171,517,587.49
五、利润总额11,201,943.9435,337,733.22214,545,726.25305,901,098.16
  减:所得税费用-9,595,212.862,560,661.089,030,410.538,541,370.3
六、净利润20,797,156.832,777,072.14205,515,315.75267,359,727.86
(一)按经营持续性分类
  持续经营净利润20,797,156.832,777,072.14205,515,315.75267,359,727.86
(二)按所有权归属分类
  归属于母公司股东的净利润20,797,156.832,777,072.14205,515,315.75267,359,727.86
  扣除非经常损益后的净利润-12,784,853.8515,415,789.2120,390,566.59196,133,309.7
七、每股收益
  (一)基本每股收益0.040.060.340.45
  (二)稀释每股收益0.040.060.340.45
九、综合收益总额20,797,156.832,777,072.14205,515,315.75267,359,727.86
  归属于母公司股东的综合收益总额20,797,156.832,777,072.14205,515,315.75267,359,727.86
公告日期2025-08-282025-04-282025-03-292024-10-30
审计意见(境内)标准无保留意见
TOP↑